Retatrutide linked to improved health-related quality of life plus weight loss
Click Here to Manage Email Alerts
Key takeaways:
- Retatrutide, a GLP-1/GIP/glucagon receptor agonist, was linked to improved health-related quality of life and weight loss vs. placebo.
- Scores of perceived hunger and disinhibition were improved with retatrutide.
SAN ANTONIO — In patients with obesity, the novel triple receptor agonist retatrutide was associated with improvement in health-related quality of life vs. placebo, a speaker reported.
At ObesityWeek, Chisom Kanu, Rph, MSc, PhD, health economics and outcomes research scientist at Eli Lilly, presented data from the phase 2 trial of evaluating the impact of a triple GLP-1/GIP/glucagon agonist retatrutide (Eli Lilly) on health-related quality of life in patients with obesity.
As Healio previously reported, in the phase 2 trial, retatrutide was associated with an up to 24.2% weight reduction in patients with obesity.
“Retatrutide is a synthetic molecule that has triple agonist action at the GLP-1, GIP and glucagon receptors,” Kanu said during the presentation. “GLP-1 receptor agonists have demonstrated beneficial effects on health-related quality of life in adults with obesity or overweight. Behavioral questionnaires have been used in earlier studies of selective In general, we’ve seen that GLP-1 receptor agonists have demonstrated beneficial effects on health-related quality of life in adults living with obesity or overweight … However, the effects of retatrutide, specifically on health-related quality of life and eating behaviors, are unknown.”
For the present analysis of 338 patients (mean age, 48.2 years; 51.8% men; mean BMI, 37.3 kg/m2), Kanu and colleagues evaluated health-related quality of life and eating behaviors among adults treated with retatrutide compared with placebo in the phase 2 trial.
The main outcomes of interest were Short Form-36 Health Survey v.2 acute form (SF-36v2) and Eating Inventory as assessed at baseline, 24 weeks and 48 weeks. The researchers also evaluated scores of cognitive restraint of eating, perceived hunger and disinhibition to assess changes in restrained eating and disinhibited eating among patients taking retatrutide.
Kanu and colleagues reported that patients with overweight or obesity treated with retatrutide 8 mg had a significantly higher SF-36v2 score compared with placebo at both 24 weeks (4.6 vs. 1.5; P < .05) and 48 weeks (4.7 vs. 2.3; P < .05).
In addition, participants assigned to any dose of retatrutide reported significantly higher perceived hunger and disinhibition scores vs. those assigned placebo at both 24 and 48 weeks (P < .01 for all comparisons); however, there was no significant difference between retatrutide and placebo in improvement in cognitive restraint of eating score.
“For those who received [retatrutide] treatment in this phase 2 trial, there was significant improvement in multiple domains of health-related quality of life compared with placebo,” Kanu said during the presentation. “We also saw reduced hunger and reduced tendency to overeat, as assessed by eating inventory, for those who received retatrutide compared to those who were on placebo. These may have contributed to the substantial weight loss associated with retatrutide treatment.
“The phase 3 clinical trials of retatrutide are ongoing in people with obesity or overweight [with or without diabetes], as well as in those who have obesity and cardiovascular disease,” she said.
Collapse
Wu Q, et al. Oral-079. Presented at: ObesityWeek; Nov. 3-6, 2024; San Antonio.
Read more about
Click Here to Manage Email Alerts